SK Bioscience-GSK Joint Sales Agreement for 5 Vaccines

[Asia Economy Reporter Cho Hyun-ui] SK Bioscience announced on the 6th that it has signed a co-promotion agreement for major vaccines with the global pharmaceutical company GSK.

This agreement is for SK Bioscience to jointly sell and distribute vaccines developed by GSK in the domestic market. The target products are five types: Tdap (tetanus, diphtheria, pertussis) vaccine 'Boostrix', meningococcal vaccine 'Menveo', hepatitis A vaccine 'Havrix1440', measles, mumps, rubella vaccine 'Priorix', and cervical cancer vaccine 'Cervarix'.

SK Bioscience will be responsible for sales in the adult market for four vaccines: Boostrix, Menveo, Havrix1440, and Priorix. Cervarix will be sold across the entire market, including infants and young children. GSK plans to focus its own sales efforts on the infant market for these vaccines while expanding its market share in the adult vaccine market through co-promotion with SK Bioscience.

The domestic market size for the five vaccines under the co-promotion agreement between SK Bioscience and GSK was approximately 128 billion KRW as of last year.

SK Bioscience stated, "Due to the COVID-19 pandemic, awareness of infectious diseases has increased, and the market is expected to expand further."

This content was produced with the assistance of AI translation services.